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OBJECTIVES We sought to compare the effects of estrogen/transvaginal progesterone gel with estrogen/
medroxyprogesterone acetate (MPA) on exercise-induced myocardial ischemia in postmeno-
pausal women with coronary artery disease or previous myocardial infarction, or both.
BACKGROUND Estrogen therapy beneficially affects exercise-induced myocardial ischemia in postmenopausal
women; however, women with an intact uterus also take progestin to protect against uterine
malignancies. The effects of combination estrogen/progestin therapy on myocardial ischemia
are unknown.
METHODS Eighteen postmenopausal women (mean 6 SD age 59 6 7 years) were given 17-beta-
estradiol in single-blinded manner for four weeks (1 mg/day for three weeks then 2 mg/day
for one week). Estradiol (2 mg/day) was then continued, and the patients were randomized
(double-blind) for 12 days to either transvaginal progesterone gel (90 mg on alternate days)
and oral MPA placebo (10 mg/day), or vice versa. After another two weeks on estradiol alone,
the patients crossed over to progestin treatment and repeated the protocol on the opposite
treatment. Patients underwent treadmill exercise testing after each estradiol phase and at day
10 of each progestin phase.
RESULTS Exercise time to myocardial ischemia increased after the first estrogen phase as compared with
baseline (mean difference with 95% confidence interval [CI]: 72 s [34 to 110], p 5 0.001),
and was increased by combination estradiol/progesterone therapy as compared with estradiol/
MPA therapy (92 s [35 to 149], p 5 0.001)). Two patients (11%) were withdrawn while
taking estradiol/MPA owing to unstable angina.
CONCLUSIONS Combination estrogen/transvaginal progesterone gel increases exercise time to myocardial
ischemia, as compared with estrogen/MPA. These results imply that the choice of progestin
in women at higher cardiovascular risk requires careful consideration. (J Am Coll Cardiol
2000;36:2154–9) © 2000 by the American College of Cardiology
Cardiovascular disease is the major cause of death in
postmenopausal women, with a fatality rate that is double
that of all forms of cancer. There is a wealth of epidemio-
logic evidence indicating that postmenopausal estrogen
therapy can significantly reduce the risk of death due to
cardiovascular disease in postmenopausal women (1). How-
ever, women with an intact uterus must also be given
progestin to prevent the increased risk of endometrial
hyperplasia and cancer seen with estrogen-only therapy.
One large epidemiologic study suggests that estrogen com-
bined with progestin results in a significantly decreased risk
of death from cardiovascular disease (2); however, this study
was not able to distinguish between different progestins.
The Heart and Estrogen Replacement Study (HERS) has
reported a null effect of long-term combined treatment with
conjugated equine estrogen and medroxyprogesterone ace-
tate (MPA) in postmenopausal women at increased risk of
coronary artery disease (CAD) events, as well as a potential
increase in the risk of myocardial infarction during the first
year of therapy (3). One of a number of reasons for the null
effect may involve inhibition of the beneficial effect of
estrogen by MPA. Investigation of the effect of progestins
in women with established CAD is therefore important.
Treatment with short- and long-term estrogen improves
exercise time to myocardial ischemia in postmenopausal
women with proven CAD (4,5). An anti-ischemic effect of
estrogen has been demonstrated using different experimen-
tal techniques in postmenopausal women (6,7). A variety of
estrogens have anti-atherogenic properties in various models
(8,9). Studies have consistently demonstrated that MPA
antagonizes the inhibitory effects of conjugated equine
estrogens on coronary artery atherosclerosis in cynomolgus
monkeys (10,11). Estrogen can protect against coronary
vasoconstriction to acetylcholine (12,13); however, recently
it has been shown that MPA can interfere with this
protection against coronary vasospasm (14). There is evi-
dence that progesterone can result in endothelium-
independent relaxation of coronary arteries at high concen-
trations (15), and that natural progesterone, unlike MPA,
does not antagonize the effect of estrogen on coronary
atheroma (10) or coronary vasospasm (14). The choice of
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progestin, particularly in patients with established CAD,
may be very important. We therefore undertook a study to
compare the effects of adding oral MPA or transvaginal
progesterone gel to estrogen therapy on exercise-induced
myocardial ischemia in postmenopausal women with proven
CAD.
METHODS
Patients. Postmenopausal women (17-beta-estradiol
,100 pmol/liter and follicular stimulating hormone [FSH]
.40 IU) with stable exertional angina (16), reproducible
positive exercise tests for myocardial ischemia, angiographi-
cally proven CAD (defined as at least 70% narrowing of the
lumen diameter in one or more of the major coronary
arteries or their major branches) and/or previous myocardial
infarction were enrolled. No patient had a myocardial
infarction in the previous six months. Patients who had
taken hormone therapy in the previous three months, were
taking digoxin, had abnormal left ventricular function or
had resting electrocardiographic (ECG) conduction abnor-
malities were excluded. The study was undertaken at two
sites; therefore, the protocol was approved by the respective
institutional Ethics Committee. All patients gave written,
informed consent.
Study design. One week before commencing the study, all
anti-anginal medications other than sublingual nitroglycerin
were withdrawn for the duration of the study. Sublingual
nitroglycerin and caffeine-containing foods were prohibited
for 3 h before each exercise test.
Patients performed a screening treadmill exercise test
according to the modified Bruce protocol. Patients with a
positive test for myocardial ischemia (ST segment depres-
sion $1 mm) then commenced a single-blind phase of
17-beta-estradiol (Estrace, Bristol Myers Squibb, Prince-
ton, New Jersey) for four weeks (1 mg/day for 18 days
followed by 2 mg/day for 10 days). Estradiol (2 mg/day) was
then continued for the duration of the study. At the end of
the fourth week, patients were randomized, in double-
blinded manner, for 12 days to either oral MPA
(10 mg/day) and transvaginal progesterone gel placebo or
MPA placebo and active transvaginal progesterone gel
(90 mg every other day; Crinone, Columbia Laboratories;
Paris, France). After another 16 days on estradiol alone, the
patients crossed over to progestin treatment and repeated
the protocol on the opposite treatment regimen. Exercise
testing was performed after each estradiol phase and on day
10 of each progestin phase (Fig. 1). Study drug compliance
was checked by a drug count at the end of each treatment
phase.
Hormone levels. A venous blood sample for measurement
of plasma levels of 17-beta-estradiol, progesterone and FSH
was taken immediately before the first screening exercise
test and before each test of the single-blind and double-
blind phases. Plasma was frozen and analyzed by chemilu-
minescence (Chiron Diagnostics) at a core laboratory to
avoid knowledge of the study treatment.
Exercise testing. Exercise tests were performed using a
Marquette CASE-15 computer-assisted recorder system.
An averaged 12-lead ECG was obtained at rest, every
minute during exercise, at the onset of anginal symptoms, at
the onset of 1-mm ST segment depression, at peak exercise
and every minute during recovery. Leads II, V2 and V5 were
continuously monitored. To accurately capture the time to
the onset of 1-mm ST segment depression, the investigator
initiated the printing of ECGs as the change from baseline
ST-segment to 1-mm ST segment depression approached,
and continued recording until the ST segment depression
decreased beyond 1 mm. Systolic and diastolic blood pres-
sures were measured at rest, at the end of each stage during
exercise and every 2 min during recovery.
A positive ECG response was defined as horizontal or
downsloping ST segment depression $1 mm at 60 ms after
the J point (17) occurring in at least two contiguous leads
and at least six consecutive complexes. Exercise tests were
concluded at the point of physical exhaustion, ST segment
depression $3 mm, severe angina, severe dyspnea or a
decline in systolic blood pressure .20 mm Hg. Total
exercise time, time to 1-mm ST segment depression, heart
rate and blood pressure at the onset of 1-mm ST segment
depression and peak exercise, maximal ST segment depres-
sion and time to development of angina during exercise were
recorded. The rate–pressure product was calculated as the
product of heart rate and systolic blood pressure.
Exercise ECGs were analyzed by an experienced inde-
pendent investigator who was unaware of the clinical data.
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
ECG 5 electrocardiographic
FSH 5 follicular stimulating hormone
HERS 5 Heart and Estrogen Replacement Study
MPA 5 medroxyprogesterone acetate
Figure 1. Flow chart of the study design. Anti-anginal medications were
stopped during the run-in phase. Patients were assigned single-blind
17-beta-estradiol (E2; 1 mg/day). On day 18 (D18), this was increased to
2 mg/day and continued for the remainder of the study. Randomization to
vaginal progesterone gel (Crinone) or MPA occurred on day 28 (D28) and
day 56 (D56). Exercise treadmill testing (ETT) was performed on day 0
(D0), D28, D38, D56 and D66. Long-dashed line 5 Crinone; short-
dashed line 5 MPA.
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The ECG lead showing the greatest ST segment depression
in the screening exercise tests was selected for analysis.
Statistical analysis. Analysis of variance was used for the
main analysis, with treatment, period and dose as fixed
variables, and patient and period within the patient as
random variables. The prestudy baseline values were con-
sidered as a covariate and were included in the analysis of
variance as such. A significant treatment–period interaction
was indicative of a carry-over effect. Validity checks were
made using the Anderson-Darling statistic, Cramer von
Mises statistic, Watson statistic and Bartlett’s test. Data
were log-transformed when the assumption of equal vari-
ances was not met (baseline and peak blood pressures and
hormone profile data only). These data are expressed as the
geometric mean value (95% confidence interval [CI]). All
other exercise data are expressed as the mean value (95%
CI). Demographic data are expressed as the mean value 6
SD. For the hormone profiles, each treatment mean value
was compared with the baseline mean value, and the
Bonferroni procedure was used to adjust the p values for
multiple comparisons. p values #0.05 were considered to be
statistically significant.
RESULTS
Patients. Twenty-six patients were enrolled. Two patients
were withdrawn due to unstable angina shortly after com-
mencing MPA treatment in combination with estrogen.
One patient withdrew while taking combination estrogen
and transvaginal progesterone gel due to heavy vaginal
bleeding, which ceased two days after stopping treatment,
and one patient withdrew because of severe breast tender-
ness after commencing the estrogen-only phase. One pa-
tient who was above the upper age limit was inadvertently
randomized but did not start treatment, one patient with-
drew after a car accident and two patients dropped out for
unspecified personal reasons. Therefore, 18 women com-
pleted the study (Table 1). Eight patients had a previous
myocardial infarction and one had previous coronary artery
bypass graft surgery. Four patients had a history of hyper-
lipidemia (range for all patients: 5.4 to 9.2 mmol/liter) and
three of these patients were taking lipid-lowering medica-
tion. All patients had clinical and biochemical evidence of
postmenopausal status (Table 2).
Hormone levels. Baseline hormonal levels confirmed the
menopausal status of the participating subjects (Table 2).
Estrogen treatment raised plasma 17-beta-estradiol (p ,
0.001) and lowered FSH (p , 0.001) (Table 2). Cyclical
treatment with MPA or vaginal progesterone further low-
ered plasma FSH (both p , 0.001) (Table 2). Plasma
progesterone increased compared with baseline when
women received progesterone gel (p , 0.001) (Table 2).
The amplitude of this elevation is concordant with the
subphysiologic levels of progesterone achieved with the
vaginal gel (18). Plasma progesterone levels, however, were
not different from baseline levels when receiving MPA (a
molecule not readily measurable). This confirms the lack of
cross-reactivity of the progesterone antibody with MPA.
The decrease in plasma FSH after MPA treatment provides
an indirect reflection of treatment compliance.
Exercise testing. Estradiol alone increased the time to
1-mm ST segment depression, as compared with baseline
(p , 0.001) (Table 3 and Fig. 2). There was a significant
increase in exercise time to the onset of 1-mm ST segment
depression by combination estradiol/progesterone as com-
pared with combination estradiol/MPA (Table 3 and Fig.
2), with a mean difference of 92 s (95% CI 35 to 149) (p ,
0.001). Nine patients demonstrated at least 1-mm ST
segment depression after taking progesterone, and 11 pa-
tients demonstrated at least 1-mm ST segment depression
after taking MPA. Five patients had a negative exercise test
for myocardial ischemia after taking both combination
progesterone and combination MPA. For analysis, total
exercise time was substituted for time to 1-mm ST segment
depression in patients who did not reach 1-mm ST segment
depression with treatment. There were no differences be-
tween the measured exercise variables after the first and
second estrogen-alone phases.
There was a trend toward an increase in total exercise
time by combination progesterone therapy as compared
with combination MPA therapy (mean difference 31 s (95%
CI 7 to 68) (p 5 0.083) (Table 3). The rate–pressure
product at rest, but not at 1-mm ST segment depression or
peak exercise, was significantly decreased after combination
progesterone therapy, as compared with after combination
Table 1. Patient Characteristics (n 5 18)
Age (yrs) 59 6 7
Time since onset of angina (yrs) 3.5 6 2.4
Hypertension 9
Non–insulin-dependent diabetes mellitus 2
Hypercholesterolemia 4
Previous myocardial infarction 8
Coronary artery disease
One vessel 4
Two vessels 9
Three vessels 5
Time since menopause (yrs) 12 6 6
Total cholesterol (mmol/liter) 6.7 6 1.1
Data are presented as the mean value 6 SD or number of patients.
Table 2. Hormone Profile After Each Treatment Period
Hormone Baseline E1 E1P E1MPA
17-beta-estradiol
(pg/ml)
26 76* 97* 87*
(21–33) (60–95) (77–122) (69–109)
Progesterone
(ng/ml)
0.25 0.27 0.89* 0.26
(0.16–0.40) (0.17–0.43) (0.57–1.41) (0.16–0.41)
FSH (IU/liter) 55 26* 17* 14*
(44–69) (21–32) (13–21) (12–18)
*p , 0.001 compared with baseline. Data are presented as the geometric mean value
(95% confidence interval).
E1 5 single-blind estradiol phase; E 1 P 5 estradiol plus progesterone phase; E
1 MPA 5 estradiol plus medroxyprogesterone acetate phase; FSH 5 follicular
stimulating hormone.
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MPA therapy (mean difference 0.926 [95% CI 0.859 to
0.998]) (p 5 0.038). Treatment with combination MPA
tended to increase the rest heart rate as compared with
combination progesterone therapy (mean difference 5 beats/
min [95% CI 0.31 to 11]) (p 5 0.058), but there was no
difference in the heart rate at 1-mm ST segment depression
or peak exercise. There was no difference in systolic blood
pressure between the treatment regimens. Treatment–
period interactions did not occur, indicating no carry-over
effect for any variable, and no training effect was shown.
DISCUSSION
Findings and comparison with previous studies. Our
results demonstrate that natural progesterone gel, when
added to estradiol treatment, results in an increase in
exercise time to myocardial ischemia compared with estro-
gen alone. In contrast, oral MPA has no effect on exercise
time to myocardial ischemia in patients already taking
estrogen. It has previously been demonstrated that both
short-term (4,6) and long-term (5) estrogen therapy can
delay the onset of signs of myocardial ischemia on the ECG
and increase exercise tolerance. The results of the present
study indicate a synergistic effect of estrogen and progester-
one, but not estrogen and MPA, on exercise time to
myocardial ischemia. This is a novel finding in the setting of
CAD.
Similar to the findings of the long-term estrogen study by
Webb et al. (5), we found no significant effect of either
combined hormone regimen on total exercise time in the
present study. However, there was a trend toward an
increase in total exercise time by combination progesterone
therapy as compared with combination MPA therapy (p 5
0.083). Studies of conventional anti-anginal therapy, such as
verapamil, have also shown a significant effect on the time to
onset of signs of myocardial ischemia, but no effect on total
exercise time (19).
Two patients (11%) developed unstable angina shortly
after commencing the MPA treatment phase (two and five
days) and were withdrawn from the study. These patients
Table 3. Effects of Estrogen Alone and Combined Therapy With Medroxyprogesterone Acetate and Progesterone at Rest and
During Exercise
Baseline E1 p Value E 1 P E 1 MPA p Value
Rest
Heart rate (beats/min) 85 86 0.71 77 82 0.058
(78–91) (77–95) (73–81) (79–86)
Systolic blood pressure (mm Hg) 146 145 0.76 137 140 0.403
(133–160) (132–158) (132–142) (135–145)
Rate–pressure product
(mm Hg 3 beats/min)
12464 12517 0.93 10470 11300 0.038
(10,829–14,099) (10,476–14,559) (9,924–11,040) (10,720–11,920)
1-mm ST segment depression
Heart rate (beats/min) 132 133 0.77 126 129 0.527
(121–142) (121–145) (121–132) (123–135)
Systolic blood pressure (mm Hg) 173 177 0.49 181 175 0.403
(160–185) (166–188) (171–191) (166–185)
Rate–pressure product
(mm Hg 3 beats/min)
22965 23647 0.64 23440 22630 0.527
(20,868–25,062) (20,878–26,416) (21,650–25,230) (20,840–24,420)
Time (s) 288 360 , 0.001 457 365 , 0.001
(204–371) (266–453) (417–497) (324–405)
Peak exercise
Heart rate (beats/min) 143 142 0.71 137 139 0.527
(134–153) (132–152) (130–143) (133–146)
Systolic blood pressure (mm Hg) 184 194 0.15 181 187 0.254
(172–197) (183–205) (173–189) (179–196)
Rate–pressure product
(mm Hg 3 beats/min)
26278 27618 0.3 25270 26620 0.343
(24,421–28,134) (25,065–30,170) (23,100–27,440) (24,450–28,790)
Time (s) 410 422 0.54 482 451 0.083
(310–510) (330–513) (456–509) (425–478)
Data are presented as the mean value (95% confidence interval).
E1 5 single-blind estradiol phase; E 1 MPA 5 estradiol plus medroxyprogesterone acetate; E 1 P 5 estradiol plus progesterone.
Figure 2. Effects of 17-beta-estradiol treatment alone (E1) and in combi-
nation with progesterone gel (P) or MPA on exercise time to the onset of
1-mm ST segment depression. Data are presented as the mean value 6
SEM.
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were successfully managed medically, then one went on to
have percutaneous transluminal coronary angioplasty. Un-
stable angina is the result of complex pathophysiology that
includes vasoconstriction, atherosclerotic plaque rupture and
platelet-induced thrombosis (20). An MPA-induced ten-
dency toward coronary vasoconstriction at the site of ath-
eroma is one possible explanation for the development of
unstable angina in these patients (14). The other possibility
is that MPA results in an increased thrombotic tendency,
although animal data suggest that this is unlikely (10).
Potential mechanisms. The observed significant increase
in time to myocardial ischemia after combination estrogen
plus progesterone gel could involve a number of mecha-
nisms. Progesterone may have a synergistic effect with
estrogen, however arguing against this is the very small
measured increase in plasma concentration of progesterone
with transvaginal progesterone gel. Another hypothesized
mechanism may be that because the plasma levels of proges-
terone were so low, our observed increase in exercise time was
purely due to an unopposed effect of a further 12 days of
estrogen therapy. As MPA has been shown in animal models
to oppose the beneficial vascular effects of estrogen, in the
present study, MPA may be nullifying a potential further
beneficial effect of more prolonged estrogen exposure on
myocardial ischemia. For example, we have shown a further
increase in the time to onset of myocardial ischemia after eight
weeks of estrogen therapy as compared with four weeks (5).
However, we showed no difference in measured exercise
variables between the first and second estrogen-alone phases.
Effects of combination hormone therapy on vascular
reactivity. Epidemiologic data suggesting a beneficial effect
of postmenopausal hormone therapy on CAD risk are
largely based on studies using unopposed estrogen; however,
combination estrogen/progestin therapy is required to de-
crease the risk of endometrial hyperplasia and subsequent
uterine carcinoma. One of the major unanswered questions
in hormone replacement therapy for hypoestrogenic women
is how to balance estrogen with progestin. This becomes
more important in patients with CAD in whom changes in
vasomotion may be detrimental. It is also particularly
pertinent because the recent HERS study reported that
continuous, combined, oral, conjugated equine estrogen
plus oral MPA did not reduce the overall rate of CAD
events in postmenopausal women with established CAD
(3). In the early phase of HERS, there was an increase in
CAD events in patients taking hormone therapy, specifi-
cally an increase in nonfatal myocardial infarction during
the first year (first few months) of starting therapy. The
survival curves then converged after one year and diverged
during the second year to show a protective effect of
hormone therapy in the latter years of the study. Although
the patients in the present study and HERS were similar—
namely, postmenopausal women with existing coronary
atherosclerosis—exercise-induced myocardial ischemia is a
measure of fixed disease in our study, as compared with the
end point of cardiovascular events in HERS. Also, different
estrogens were used: HERS used a continuous, combined
preparation, whereas a cyclical regimen was used in the
present study.
It is possible that MPA may oppose the vasodilator
actions of estrogen, as has been demonstrated in animal
models (21). Miyagawa et al. (14) studied the effect of
physiologic levels of 17-beta-estradiol combined with MPA
or progesterone on coronary vasomotion in ovariectomized
rhesus monkeys. Coronary vasospasm was demonstrated in
response to physiologic stimulation without injury when the
animals were treated with MPA plus estradiol, but not when
treated with progesterone plus estradiol. This latter combi-
nation protected against acetylcholine-induced vasospasm.
These investigators concluded that MPA, in contrast to
progesterone, increases the risk of coronary vasospasm. This
finding concurs with our findings in that two patients were
withdrawn from the study because of unstable angina after
the initiation of the MPA phase of the study.
Effects of combination hormone therapy on atheroscle-
rosis. In addition to its effect on vasomotor tone, MPA
antagonizes the inhibitory effects of conjugated equine
estrogens on coronary atherosclerosis in cynomolgus mon-
keys (10) and of 17-beta-estradiol in the rat carotid artery.
This may be at least partially due to an inhibitory effect of
MPA on the beneficial lipid effects of estrogen. In the
Postmenopausal Estrogen-Progestin Interventions (PEPI)
trial, MPA partially inhibited the estrogen-associated in-
crease in HDL cholesterol more than micronized proges-
terone (22). However observational studies have shown a
similar reduction in coronary heart disease risk in women
using MPA plus estrogen as in women taking unopposed
estrogen (23). There are a number of reports that clearly
show a detrimental effect of MPA on the beneficial effects of
conjugated equine estrogens with regard to atheroma devel-
opment (10,11) and vascular reactivity (14,21). There are
also studies showing that progesterone does not appear to
have this inhibitory effect either on atheroma development
(8,24) or vascular reactivity in animal models (14,15), nor on
vascular reactivity in humans (25). Progesterone has an
anti-smooth muscle proliferative effect in vitro (26), a
feature that may be important in that atherosclerotic plaques
of women who have suffered acute sudden death have more
smooth muscle cell proliferation than male subjects (27).
Study limitations. The present study was designed to
investigate whether the addition of progestins in women
taking estrogen affects the anti-ischemic properties of estro-
gen. The design might have included a progestin placebo-
placebo arm or might have given the estradiol in a double-
blind, placebo-controlled fashion. However, this would
have added to the already complex design of the study and
may not have contributed any further to the current knowl-
edge in this field. Indeed, previous randomized, placebo-
controlled studies have reported effects of estrogen alone on
myocardial ischemia (4–6).
Conclusions. Both the present study and HERS argue that
the choice of progestin may be important in higher risk
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women with established CAD. The choice of natural
progesterone in this group of patients would seem more
appropriate, as natural progesterone gel enhances the effects
of estrogen on exercise-induced myocardial ischemia. Fur-
ther randomized studies investigating different estrogens
and progestins, as well as doses and routes of administration
in different patient groups, will be required before definitive
conclusions can be made about the use of hormone therapy
in postmenopausal women who have, or are at increased risk
of having, cardiovascular disease.
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